From chromosomal abnormalities to the identification of target genes in mouse models of breast cancer

Cancer Genetics

Volumn 207, Issue 6, 2014, Pages 233-246

  Fabris, Victoria T ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Breast cancer; Carcinogenesis; Cytogenetics; Karyotype; Mouse model

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE PHOSPHATASE; VIRUS T ANTIGEN; WNT1 PROTEIN;

ANIMAL CELL; ANIMAL MODEL; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CELL CYCLE; CHROMOSOME 11; CHROMOSOME 11Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 22Q; CHROMOSOME 3P; CHROMOSOME 4; CHROMOSOME 4P; CHROMOSOME 6Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; CHROMOSOME DOUBLING; CHROMOSOME G BAND; CHROMOSOME LOSS; COPY NUMBER VARIATION; CYTOGENETICS; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; KARYOTYPE; MITOSIS; MOUSE; NONHUMAN; ONCOGENE C MYC; ONCOGENE RAS; REVIEW; TRP53 GENE; ANIMAL; BREAST TUMOR; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; HUMAN;

ANIMALS; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CYTOGENETICS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE;

EID: 84907664352     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.06.025     Document Type: Review

References (72)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 62:10-29.
2. Hoglund M., Frigyesi A., Sall T., et al. Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 2005, 42:327-341.
3. Climent J., Garcia J.L., Mao J.H., et al. Characterization of breast cancer by array comparative genomic hybridization. Biochem Cell Biol 2007, 85:497-508.
4. Carlow D.A., Kerbel R.S., Feltis J.T., et al. Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. JNatl Cancer Inst 1985, 75:291-301.
5. Frost P., Kerbel R.S., Hunt B., et al. Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. Cancer Res 1987, 47:2690-2695.
6. Elliott B.E., Xu W., Mudrik K., et al. Karyotypic evolution of a murine mammary adenocarcinoma invitro and during progression from primary to metastatic growth invivo. Genes Chromosomes Cancer 1992, 4:281-289.
7. Simian M., Manzur T., Rodriguez V., et al. Aspontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice. Breast Cancer Res Treat 2009, 113:1-8.
8. Pontiggia O., Rodriguez V., Fabris V., et al. Establishment of an invitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat 2009, 116:247-255.
9. Aldaz C.M., Liao Q.Y., Paladugu A., et al. Allelotypic and cytogenetic characterization of chemically induced mouse mammary tumors: high frequency of chromosome 4 loss of heterozygosity at advanced stages of progression. Mol Carcinog 1996, 17:126-133.
10. Brenner A.J., Aldaz C.M. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 1995, 55:2892-2895.
11. Brenner A.J., Paladugu A., Wang H., et al. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res 1996, 2:1993-1998.
12. Currier N., Solomon S.E., Demicco E.G., et al. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol 2005, 33:726-737.
13. Melnick R.L., Huff J., Chou B.J., et al. Carcinogenicity of 1,3-butadiene in C57BL/6 x C3H F1 mice at low exposure concentrations. Cancer Res 1990, 50:6592-6599.
14. Wiseman R.W., Cochran C., Dietrich W., et al. Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. Proc Natl Acad Sci USA 1994, 91:3759-3763.
15. Zhuang S.M., Wiseman R.W., Söderkvist P. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice. Oncogene 2002, 21:5643-5648.
16. Lanari C., Molinolo A.A., Pasqualini C.D. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett 1986, 33:215-223.
17. Lanari C., Lamb C.A., Fabris V.T., et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009, 16:333-350.
18. Helguero L.A., Viegas M., Asaithamby A., et al. Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res Treat 2003, 79:379-390.
19. Fabris V.T., Benavides F., Conti C., et al. Cytogenetic findings, Trp53 mutations, and hormone responsiveness in a medroxyprogesterone acetate induced murine breast cancer model. Cancer Genet Cytogenet 2005, 161:130-139.
20. Giulianelli S., Herschkowitz J.I., Patel V., et al. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. Breast Cancer Res Treat 2011, 129:49-67.
21. Xu J., Chen Y., Olopade O.I. Breast Cancer. Genes Cancer 2010, 1:629-640.
22. Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
23. D'Cruz C.M., Gunther E.J., Boxer R.B., et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001, 7:235-239.
24. McCormack S.J., Weaver Z., Deming S., et al. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 1998, 16:2755-2766.
25. Weaver Z.A., McCormack S.J., Liyanage M., et al. Arecurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer 1999, 25:251-260.
26. Hutchinson J.N., Muller W.J. Transgenic mouse models of human breast cancer. Oncogene 2000, 19:6130-6137.
27. Guy C.T., Webster M.A., Schaller M., et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89:10578-10582.
28. Ritland S.R., Rowse G.J., Chang Y., et al. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 1997, 57:3520-3525.
29. Bouchard L., Lamarre L., Tremblay P.J., et al. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989, 57:931-936.
30. Cool M., Jolicoeur P. Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice. Cancer Res 1999, 59:2438-2444.
31. Nagai H., Negrini M., Carter S.L., et al. Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 1995, 55:1752-1757.
32. Marsh K.L., Varley J.M. Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast. Br J Cancer 1998, 77:1439-1447.
33. Geradts J., Wilson P.A. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol 1996, 149:15-20.
34. Hui R., Macmillan R.D., Kenny F.S., et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000, 6:2777-2787.
35. Gorgoulis V.G., Koutroumbi E.N., Kotsinas A., et al. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med 1998, 4:807-822.
36. Dietrich W.F., Lander E.S., Smith J.S., et al. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 1993, 75:631-639.
37. Jeruss J.S., Liu N.X., Chung Y., et al. Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis 2003, 24:659-664.
38. Andrechek E.R., Hardy W.R., Siegel P.M., et al. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 2000, 97:3444-3449.
39. Montagna C., Andrechek E.R., Padilla-Nash H., et al. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 2002, 21:890-898.
40. D'Amico M., Wu K., Di Vizio D., et al. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res 2003, 63:3395-3402.
41. Smith C.A., Pollice A.A., Gu L.P., et al. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 2000, 6:112-126.
42. Sinn E., Muller W., Pattengale P., et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes invivo. Cell 1987, 49:465-475.
43. Radany E.H., Hong K., Kesharvarzi S., et al. Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4. Proc Natl Acad Sci USA 1997, 94:8664-8669.
44. Hundley J.E., Koester S.K., Troyer D.A., et al. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol 1997, 17:723-731.
45. Le Roy H., Ricoul M., Ogata H., et al. Chromosome anomalies in mammary carcinoma from transgenic WAPRAS mice: compression with human data. Genes Chromosomes Cancer 1993, 6:156-160.
46. Welcsh P.L., King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001, 10:705-713.
47. Xu X., Wagner K.U., Larson D., et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999, 22:37-43.
48. Weaver Z., Montagna C., Xu X., et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002, 21:5097-5107.
49. Brodie S.G., Xu X., Qiao W., et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001, 20:7514-7523.
50. Grushko T.A., Dignam J.J., Das S., et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004, 10:499-507.
51. Smolen G.A., Muir B., Mohapatra G., et al. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 2006, 66:3452-3455.
52. Shakya R., Szabolcs M., McCarthy E., et al. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci USA 2008, 105:7040-7045.
53. Ludwig T., Fisher P., Murty V., et al. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 2001, 20:3937-3948.
54. Cui X.S., Donehower L.A. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53. Oncogene 2000, 19:5988-5996.
55. Donehower L.A., Godley L.A., Aldaz C.M., et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 1995, 9:882-895.
56. Umesako S., Iiga S., Takahashi M., et al. Distinct pattern of allelic loss and inactivation of cadherin 1 and 5 genes in mammary carcinomas arising in p53(+/-) mice. JRadiat Res (Tokyo) 2007, 48:143-152.
57. Medina D., Kittrell F.S., Shepard A., et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J 2002, 16:881-883.
58. Medina D., Kittrell F.S., Shepard A., et al. Hormone dependence in premalignant mammary progression. Cancer Res 2003, 63:1067-1072.
59. Abba M.C., Fabris V.T., Hu Y., et al. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 2007, 67:4104-4112.
60. Meyer R., Fofanov V., Panigrahi A., et al. Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers. Clin Cancer Res 2009, 15:2703-2710.
61. Zhang N., Ge G., Meyer R., et al. Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc Natl Acad Sci USA 2008, 105:13033-13038.
62. Nguyen H.G., Makitalo M., Yang D., et al. Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J 2009, 23:2741-2748.
63. Ray D., Terao Y., Fuhrken P.G., et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res 2007, 67:984-991.
64. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992, 12:954-961.
65. Maglione J.E., Moghanaki D., Young L.J., et al. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001, 61:8298-8305.
66. Desai K.V., Xiao N., Wang W., et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002, 99:6967-6972.
67. Montagna C., Lyu M.S., Hunter K., et al. The septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. Cancer Res 2003, 63:2179-2187.
68. Green J.E., Shibata M.A., Yoshidome K., et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000, 19:1020-1027.
69. Ried T., Dorritie K., Weaver Z., et al. Molecular cytogenetics of mouse models of breast cancer. Breast Dis 2004, 19:59-67.
70. Connolly D., Yang Z., Castaldi M., et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res 2011, 13:R76.
71. Melchor L., Saucedo-Cuevas L.P., Munoz-Repeto I., et al. Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 2009, 11:R86.
72. Herschkowitz J.I., Simin K., Weigman V.J., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76.